Amendments to the Claims

This Listing of Claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) A compound of formula I



I

wherein

R_1 is ~~C_{1-6}alkyl optionally substituted by OH, C_{1-2}alkoxy or 1 to 6 fluorine atoms; C_{2-6}alkenyl; or C_{2-6}alkynyl~~ methyl;

R_2 is a residue of formula (c)

-Y'-(CH_2)n-(CF_2)m-CHpFq (c)

wherein

Y' is a direct bond, O, CO, CHOH or C=NOR_6 wherein R_6 is H, C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4} alkynyl or benzyl;

n is 0, 1,2, 3, 4 or 5;

m is 0, 1, 2, 3, 4, 5 or 6, provided that the sum of n+m is 3-8;

each of p and q, independently, is 0, 1, 2 or 3; with the proviso that p + q = 3;

the chain (CH_2)n-(CF_2)m-CHpFq being optionally interrupted by one carbon-carbon double or triple bond, one CO or one or two oxygen atoms ~~R_2' or R_2''~~

~~wherein R_2' is X_1, -O-X_1, -CO-X_1, -CH(OH)-X_1, -C(=NOR_6)-X_1, -S-X_1, -SO-X_1, -SO_2-X_1 or -N(C_{1-6}alkyl)-X_1, wherein X_1 is C_{3-8}alkyl substituted by 1 to 17 fluorine atoms and optionally interrupted in the carbon chain by one or more O, C=O, CH-OH or C=NOR_6 and/or one carbon-carbon double or triple bond; pentyl substituted by C_{1-3}alkyl and optionally interrupted in the carbon chain by one or more O, C=O, CH-OH or C=NOR_6 and/or one carbon-carbon double or triple bond; C_{2-8}alkyl-C_{3-6}cycloalkyl wherein the C_{2-8}alkyl moiety is optionally interrupted in the carbon chain by one or more O, C=O, CH-OH or C=NOR_6 and/or one carbon-carbon double or triple bond, and the C_{3-6}cycloalkyl and/or the C_{2-8}alkyl is substituted by 1 to 17 fluorine atoms; and each of R_6, independently, is H, C_{1-4} alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl or benzyl; and~~

~~and wherein R_2'' is X-CH_2-CH_2-R attached in position para, wherein X is O, CH_2, or C=O; and R is a residue of formula (b)~~



(b)

~~wherein each of R_7 to R_{11}, independently, is H; Cl; Br; F; CN; CF_3; OCF_3; $OCHF_2$; C_{1-6}alkyl; C_{1-6}alkoxy; C_{3-6}cycloalkyl; C_{3-6}cycloalkoxy; acyl; or optionally substituted phenyl; or R_9 and R_{10} form together 3,4-[-$O(CH_2)_rO$-] wherein r is 1 or 2; or (R_7 and R_8) or (R_8 and R_9) together with the carbon atoms to which they are attached, form a fused cyclic or heterocyclic ring and the remaining R_9 to R_{11} or R_7 and R_{10} and R_{11}, respectively, are as defined above; or R is α- or β-naphthyl optionally substituted by one to 5 substituents as defined above for R_7 to R_{11};~~

R_3 is Z-X_2 wherein Z is CH_2, CHF or CF_2 or CHMe and X_2 is OH or a residue of formula (a)



(a)

wherein Z_1 is a direct bond, CH_2, CHF, CF_2 or O, and each of R_{12} and R_{13}, independently, is H or C_{1-4} alkyl optionally substituted by 1, 2 or 3 halogen atoms; and each of R_4 and R_5, independently, is H, C_{1-4}alkyl optionally substituted by 1, 2 or 3 halogen atoms, or acyl

in free form or in salt form.

2. (Currently Amended) A compound according to claim 1 wherein R_2 ~~is R_2' which is X_1, -O-X_1, -CO-X_1, -CH(OH)-X_1 or -C(NOR$_6$)-X_1~~ is selected from the group consisting of:

-Y-C_nF_{2n+1} wherein n=3-8 and Y is CH_2, O or C=O;

-Y-$CH_2C_nF_{2n+1}$ wherein n=1-7and Y is CH_2, O or C=O;

-Y-$CH_2CH_2C_nF_{2n+1}$ wherein n=1-6 and Y is CH_2, O or C=O;

-Y-$CH_2CH_2CH_2C_nF_{2n+1}$ wherein n=1-5 and Y is CH_2, O or C=O;

-Y-$(CH_2)_nF$ wherein n=1-7 and Y is CH_2, O or C=O;

-Y-$(CH_2)_nCF_3$ wherein n=1-6 and Y is CH_2, O or C=O;

-Y-$(CH_2)_nCF_2CH_3$ wherein n=1-4 and Y is CH_2, O or C=O;

-Y-$(CH_2)_n(CF_2)_mCHF_2$ wherein n=0-3, m=1-6, n+m = 3-7 and Y is CH_2, O or C=O; and

-Y-$(CH_2)_nC(O)CF_3$ wherein n=1-5 and Y is CH_2, O or C=O.

3.–7. (Canceled)

8. (Previously Presented) A pharmaceutical composition comprising a compound according claim 1, or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable diluent or carrier therefor.

9. (Previously Presented) A pharmaceutical combination comprising a compound according to claim 1, in free form or in pharmaceutically acceptable salt form, and at least one co-agent selected from an immunosuppressant agent, an immunomodulatory agent, and anti-inflammatory or chemotherapeutic drug.

10. (Previously Presented) A method for treating disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell mediated inflammatory or autoimmune diseases in a subject comprising administering to the subject in need thereof an effective amount of a compound according claim 1, or a pharmaceutically acceptable salt thereof.

11.-19. (Canceled)